Clinical trial
One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant…
NCT00246467 · PharmAthene UK Limited, Industry · Completed
Key facts
| NCT number | NCT00246467 |
|---|---|
| Title | One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens) |
| Official title | A Phase 1b, Multi-Centre, Parallel Group, Single Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Plague Vaccine (rF1 and rV Antigens) in Healthy Subjects |
| Lead sponsor | PharmAthene UK Limited, Industry |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Plague |
| Intervention type | Biological |
| Interventions | Alhydrogel, rF1 and rV protein antigens |
| Enrollment | 123 |
| Start date | Oct 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Oct 31, 2005 |
| Last update posted | Sep 15, 2008 |
| Countries | United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: